Deferoxamine Mesylate

甲磺酸去铁胺

Report date: 2025/11/29 20:00:12
NME

Base Information

Drug NameDeferoxamine Mesylate
Drug Alias NameDesferrioxamine Mesylate甲磺酸除铁灵甲磺酸去铁敏Deferoxamine Mesilate去铁胺甲磺酸酯 +[11] 
ClassificationSmall molecules > Polymers and chelators
Mechanisms of ActionIron chelating agents
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Ischemic StrokeIron Overload +[17] 
Global Approved IndicationsIron Overload
Approved Indications in ChinaN/A
Original Approved Country/TerritoryNew Zealand
Original Approved Date1962/12/01
Country/TerritoryCanadaUnited StatesNetherlands +[8] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaDiscontinued
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesRadboud University Medical CenterMitem PharmaThe Brigham and Women's Hospital +[4] 
Inactive CompaniesKermanshah University Of Medical SciencesTautona GroupMedical University Of South Carolina +[7] 
Active IndicationsIron OverloadAcute Kidney InjurySubarachnoid Hemorrhage +[4] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Ischemic StrokeSkin Ulcer +[13] 

Other Information

ATC CodeV03AC01
Related LinksWikipediaDrugBankKEGG